Sagimet Biosciences Q2 net loss widens on higher R&D costs

Sagimet Biosciences

11/08/2026 12:38

Overview
Biopharmaceutical firm's Q2 net loss widened yr/yr as R&D expenses increased
Company completed $175 mln equity financing in April 2026
Cash position of $257.6 mln expected to fund operations through 2028

Outlook
Sagimet expects cash reserves to fund operations through 2028, including Phase 3 denifanstat data readout

Result Drivers
R&D SPENDING - Increased research and development expenses as company advanced clinical programs, including denifanstat for acne
EQUITY FINANCING - Completed $175 mln equity financing in April 2026 to support clinical development and operations

Company press release: ID:nGNX6l2l47

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$13.95 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Sagimet Biosciences Inc. is $28.00, about 192.6% above its August 10 closing price of $9.57

Reuters Recommended Reads
Aug 10 - Oruka Therapeutics Q2 net loss widens on higher R&D costs
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Aug 11 - Germany's Dermapharm prelim H1 revenue rises, maintains outlook

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)